Cencora (COR) Stock Price, News & Analysis

Company Overview

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers.

The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.

Cencora serves customers in the United States and internationally. The company adopted the Cencora name in 2023, reflecting its global reach and its role across the pharmaceutical supply chain.

Key Stats

• Today's Range: $350.11 to $359.39
• 50-Day Range: $300.71 to $359.12
• 52-Week Range: $244.82 to $377.54
• Volume: 1.39 million shs
• Average Volume: 1.42 million shs
• Market Capitalization: $68.53 billion
• P/E Ratio: 20.04
• Dividend Yield: 0.67%
• Price Target: $368.14
• Consensus Rating: Moderate Buy

Cencora Stock Analysis - MarketRank™

Cencora scored higher than 93% of companies evaluated by MarketBeat, and ranked 11th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cencora has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 12 buy ratings, 4 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Cencora is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Cencora has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.32%

Earnings Growth

Earnings for Cencora are expected to grow by 10.32% in the coming year, from $19.58 to $21.60 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cencora is 19.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.03.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cencora is 19.44, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.39.

Price to Earnings Growth Ratio

Cencora has a PEG Ratio of 1.81. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Cencora has a P/B Ratio of 18.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.66% of the float of Cencora has been sold short.

Short Interest Ratio / Days to Cover

Cencora has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cencora has recently decreased by 19.75%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Cencora has a dividend yield of 0.69%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Cencora has been increasing its dividend for 15 years.

Dividend Coverage

The dividend payout ratio of Cencora is 13.39%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Cencora will have a dividend payout ratio of 11.11% next year. This indicates that Cencora will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.74

News Sentiment

Cencora has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Cencora this week, compared to 7 articles on an average week.

Search Interest

22 people have searched for COR on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days.

MarketBeat Follows

9 people have added Cencora to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cencora insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,662,556.00 in company stock.

Percentage Held by Insiders

0.38% of the stock of Cencora is held by insiders.

Percentage Held by Institutions

97.52% of the stock of Cencora is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 8/31 Dividend: 8/14/2026
• Ex-Dividend for 8/31 Dividend: 8/14/2026
• Dividend Payable: 8/31/2026
• Last Earnings: 11/04/2026
• Record date for 11/30 Dividend: 11/13/2026
• Ex-Dividend for 11/30 Dividend: 11/13/2026
• Today: 11/14/2026
• Dividend Payable: 11/30/2026
• Fiscal Year End: 9/30/2027

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Distributors
• Current Symbol: NYSE:COR
• CIK: 1140859
• Web: www.cencora.com
• Phone: (610) 727-7000
• Fax: 800-640-5221
• Employees: 51,000
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Cencora: $368.14
• High Price Target: $413.00
• Low Price Target: $310.00
• Potential Upside/Downside: +2.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): $17.92
• Trailing P/E Ratio: 19.44
• Forward P/E Ratio: 16.63
• P/E Growth: 1.81
• Net Income: $3.48 billion
• Net Margins: 1.03%
• Pretax Margin: 1.36%
• Return on Equity: 110.72%
• Return on Assets: 4.22%

Debt

• Debt-to-Equity Ratio: 3.01
• Current Ratio: 0.94
• Quick Ratio: 0.59

Sales & Book Value

• Annual Sales: $337.40 billion
• Price / Sales: 0.20
• Cash Flow: $25.76 per share
• Price / Cash Flow: 13.94
• Book Value: $19.29 per share
• Price / Book: 18.62

Miscellaneous

• Outstanding Shares: 190,830,000
• Free Float: 190,102,000
• Market Cap: $68.53 billion
• Optionable: Optionable
• Beta: 0.58